Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| SYNLOGIC, INC.MIRN · Entity 7801 | Director | June 29, 2016 | September 06, 2016 |
| TEVA PHARMACEUTICAL INDUSTRIES LTDTEVA · Entity 3063 | Director | June 05, 2026 | June 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
SYNLOGIC, INC.
Report date June 29, 2016 · Filed September 06, 2016
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.74 · Expires 2016-06-29 | Direct | 20,000 |
Reported balance
After 2016-06-29 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2016-06-29 · Grant · Acquired 20,000 · Balance 20,000 F1: The option vests with respect to 1/3 of the shares subject thereto on each yearly anniversary of June 29, 2016, subject to the Reporting Person continuing to provide services to the Issuer through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests with respect to 1/3 of the shares subject thereto on each yearly anniversary of June 29, 2016, subject to the Reporting Person continuing to provide services to the Issuer through each such vesting date.
TEVA PHARMACEUTICAL INDUSTRIES LTD
Report date June 05, 2026 · Filed June 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 119,807 |
Reported balance
After 2026-06-05 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-05 · Exercise / conversion · Acquired 14,492 · Balance 119,807 F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. |
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-05 · Exercise / conversion · Disposed 14,492 · Balance 0 F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3: Restricted share units were granted on June 5, 2025 and vested on June 5, 2026. F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. |
Filing footnotes · ownership attribution and instrument terms
F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
F3: Restricted share units were granted on June 5, 2025 and vested on June 5, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 05, 2026 Filed Jun 8, 2026 20:04 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 14,492 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-261688 · ownership.xml · derivative · entry 2 Nisen Perry · CIK 0001683791 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 14,492 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted share units were granted on June 5, 2025 and vested on June 5, 2026. F3 · derivative.expiration_date: Restricted share units were granted on June 5, 2025 and vested on June 5, 2026. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| June 05, 2026 Filed Jun 8, 2026 20:04 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 14,492 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-261688 · ownership.xml · nonDerivative · entry 1 Nisen Perry · CIK 0001683791 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 119,807 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| May 28, 2026 Filed Jun 1, 2026 20:13 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 7,242 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-251441 · ownership.xml · derivative · entry 1 Nisen Perry · CIK 0001683791 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,242 Underlying: Ordinary Shares · 7,242 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Restricted share units were granted on May 28, 2026 and vest on May 28, 2027. F2 · derivative.expiration_date: Restricted share units were granted on May 28, 2026 and vest on May 28, 2027. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| June 06, 2025 Filed Jun 9, 2025 20:15 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 9,632 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-083749 · ownership.xml · derivative · entry 2 Nisen Perry · CIK 0001683791 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 9,632 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted share units were granted on June 6, 2024 and vested on June 6, 2025. F3 · derivative.expiration_date: Restricted share units were granted on June 6, 2024 and vested on June 6, 2025. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| June 06, 2025 Filed Jun 9, 2025 20:15 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 9,632 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-083749 · ownership.xml · nonDerivative · entry 1 Nisen Perry · CIK 0001683791 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,315 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 20:15 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 14,492 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-083749 · ownership.xml · derivative · entry 3 Nisen Perry · CIK 0001683791 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,492 Underlying: Ordinary Shares · 14,492 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F4 · derivative.exercise_date: Restricted share units were granted on June 5, 2025 and vest on June 5, 2026. F4 · derivative.expiration_date: Restricted share units were granted on June 5, 2025 and vest on June 5, 2026. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| June 15, 2024 Filed Jun 17, 2024 11:27 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 21,108 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-074015 · ownership.xml · derivative · entry 2 Nisen Perry · CIK 0001683791 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 21,108 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted Share Units were granted on June 15, 2023 and vested on June 15, 2024. F3 · derivative.expiration_date: Restricted Share Units were granted on June 15, 2023 and vested on June 15, 2024. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| June 15, 2024 Filed Jun 17, 2024 11:27 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 21,108 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-074015 · ownership.xml · nonDerivative · entry 1 Nisen Perry · CIK 0001683791 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,683 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| June 06, 2024 Filed Jun 10, 2024 11:42 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 9,632 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-071070 · ownership.xml · derivative · entry 1 Nisen Perry · CIK 0001683791 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,632 Underlying: Ordinary Shares · 9,632 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Restricted share units were granted on June 6, 2024 and vest on June 6, 2025. F2 · derivative.expiration_date: Restricted share units were granted on June 6, 2024 and vest on June 6, 2025. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| August 04, 2023 Filed Aug 7, 2023 20:08 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 15,810 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-044787 · doc4.xml · derivative · entry 2 Nisen Perry · CIK 0001683791 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 15,810 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted share units were granted on August 4, 2022 and vested on August 4, 2023. F3 · derivative.expiration_date: Restricted share units were granted on August 4, 2022 and vested on August 4, 2023. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| August 04, 2023 Filed Aug 7, 2023 20:08 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 15,810 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-044787 · doc4.xml · nonDerivative · entry 1 Nisen Perry · CIK 0001683791 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,575 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| June 15, 2023 Filed Jun 20, 2023 11:36 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 21,108 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-038222 · doc4.xml · derivative · entry 1 Nisen Perry · CIK 0001683791 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,108 Underlying: Ordinary Shares · 21,108 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Restricted share units were granted on June 15, 2023 and vest on June 15, 2024. F2 · derivative.expiration_date: Restricted share units were granted on June 15, 2023 and vest on June 15, 2024. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| August 04, 2022 Filed Aug 8, 2022 11:22 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 15,810 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-044696 · doc4.xml · derivative · entry 1 Nisen Perry · CIK 0001683791 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,810 Underlying: Ordinary Shares · 15,810 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Restricted share units were granted on August 4, 2022 and vest on August 4, 2023. F2 · derivative.expiration_date: Restricted share units were granted on August 4, 2022 and vest on August 4, 2023. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 11:40 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 14,479 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-037250 · doc4.xml · derivative · entry 2 Nisen Perry · CIK 0001683791 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 14,479 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted share units were granted on June 14, 2021 and vested on June 14, 2022. F3 · derivative.expiration_date: Restricted share units were granted on June 14, 2021 and vested on June 14, 2022. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 11:40 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 14,479 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-037250 · doc4.xml · nonDerivative · entry 1 Nisen Perry · CIK 0001683791 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,765 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| June 14, 2021 Filed Jun 16, 2021 12:20 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 14,479 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-040812 · doc4.xml · derivative · entry 1 Nisen Perry · CIK 0001683791 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,479 Underlying: Ordinary Shares · 14,479 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Restricted share units were granted on June 14, 2021 and vest on June 14, 2022. F2 · derivative.expiration_date: Restricted share units were granted on June 14, 2021 and vest on June 14, 2022. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| June 09, 2021 Filed Jun 10, 2021 11:45 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 12,668 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-039373 · doc4.xml · derivative · entry 2 Nisen Perry · CIK 0001683791 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 12,668 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted share units were granted on June 9, 2020 and vested on June 9, 2021. F3 · derivative.expiration_date: Restricted share units were granted on June 9, 2020 and vested on June 9, 2021. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| June 09, 2021 Filed Jun 10, 2021 11:45 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 12,668 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-039373 · doc4.xml · nonDerivative · entry 1 Nisen Perry · CIK 0001683791 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,286 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| June 05, 2021 Filed Jun 8, 2021 11:30 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 6,041 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-038817 · doc4.xml · derivative · entry 2 Nisen Perry · CIK 0001683791 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 6,041 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted share units were granted on June 5, 2018 and vested on June 5, 2021. F3 · derivative.expiration_date: Restricted share units were granted on June 5, 2018 and vested on June 5, 2021. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| June 05, 2021 Filed Jun 8, 2021 11:30 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 6,041 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-038817 · doc4.xml · nonDerivative · entry 1 Nisen Perry · CIK 0001683791 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,618 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| August 11, 2020 Filed Aug 13, 2020 20:14 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 7,956 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-046594 · doc4.xml · derivative · entry 2 Nisen Perry · CIK 0001683791 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 7,956 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted share units were granted on August 11, 2017 and vested on August 11, 2020. F3 · derivative.expiration_date: Restricted share units were granted on August 11, 2017 and vested on August 11, 2020. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| August 11, 2020 Filed Aug 13, 2020 20:14 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 7,956 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-046594 · doc4.xml · nonDerivative · entry 1 Nisen Perry · CIK 0001683791 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,577 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| June 11, 2020 Filed Jun 15, 2020 11:35 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 17,621 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-036500 · doc4.xml · derivative · entry 2 Nisen Perry · CIK 0001683791 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 17,621 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted share units were granted on June 11, 2019 and vested on June 11, 2020. F3 · derivative.expiration_date: Restricted share units were granted on June 11, 2019 and vested on June 11, 2020. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| June 11, 2020 Filed Jun 15, 2020 11:35 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 17,621 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-036500 · doc4.xml · nonDerivative · entry 1 Nisen Perry · CIK 0001683791 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,621 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| June 09, 2020 Filed Jun 11, 2020 11:14 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 12,668 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-035786 · doc4.xml · derivative · entry 1 Nisen Perry · CIK 0001683791 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,668 Underlying: Ordinary Shares · 12,668 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Restricted share units were granted on June 9, 2020 and vest on June 9, 2021. F2 · derivative.expiration_date: Restricted share units were granted on June 9, 2020 and vest on June 9, 2021. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| June 11, 2019 Filed Jun 13, 2019 10:28 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 17,621 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-036591 · doc4.xml · derivative · entry 1 Nisen Perry · CIK 0001683791 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,621 Underlying: Ordinary Shares · 17,621 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Restricted share units were granted on June 11, 2019 and vest on June 11, 2020. F2 · derivative.expiration_date: Restricted share units were granted on June 11, 2019 and vest on June 11, 2020. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| June 05, 2018 Filed Jun 7, 2018 10:46 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 6,041 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-036196 · doc4.xml · derivative · entry 1 Nisen Perry · CIK 0001683791 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,041 Underlying: Ordinary Shares · 6,041 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Restricted share units were granted on June 5, 2018 and vest on June 5, 2021. F2 · derivative.expiration_date: Restricted share units were granted on June 5, 2018 and vest on June 5, 2021. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| June 29, 2016 Filed Sep 6, 2016 22:23 UTC | SYNLOGIC, INC. MIRN · Entity 7801 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $4.74 | $0.00 |
DisclosureSEC source: 0001140361-16-078989 · doc1.xml · derivative · entry 1 Nisen Perry · CIK 0001683791 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2016-06-29 F1 · derivative.exercise_date: The option vests with respect to 1/3 of the shares subject thereto on each yearly anniversary of June 29, 2016, subject to the Reporting Person continuing to provide services to the Issuer through each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.